[
    [
        {
            "time": "",
            "original_text": "康龙化成：康君仲元拟引进公司关联方作为基金合伙人",
            "features": {
                "keywords": [
                    "康龙化成",
                    "康君仲元",
                    "基金合伙人",
                    "关联方"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康龙化成：康君仲元拟引进公司关联方作为基金合伙人",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康龙化成(03759)：康君仲元拟引进公司关联方作为基金合伙人",
            "features": {
                "keywords": [
                    "康龙化成",
                    "股票代码",
                    "康君仲元",
                    "基金合伙人"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康龙化成(03759)：康君仲元拟引进公司关联方作为基金合伙人",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：医药板块估值已具备吸引力 建议长期配置优质赛道",
            "features": {
                "keywords": [
                    "医药生物",
                    "估值",
                    "吸引力",
                    "长期配置",
                    "优质赛道"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业周报：医药板块估值已具备吸引力 建议长期配置优质赛道",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：短期受政策扰动 关注中报高成长个股",
            "features": {
                "keywords": [
                    "医药生物",
                    "政策扰动",
                    "中报",
                    "高成长个股"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报：短期受政策扰动 关注中报高成长个股",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【异动股】康龙化成(03759.HK)涨3.34%",
            "features": {
                "keywords": [
                    "康龙化成",
                    "股票代码",
                    "涨3.34%"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【异动股】康龙化成(03759.HK)涨3.34%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 6,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "CXO板块逆势走强，康龙化成涨超5%再创新高",
            "features": {
                "keywords": [
                    "CXO板块",
                    "逆势走强",
                    "康龙化成",
                    "涨超5%",
                    "新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CXO板块逆势走强，康龙化成涨超5%再创新高",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "后疫情时代，关注科技成长板块投资机会",
            "features": {
                "keywords": [
                    "后疫情时代",
                    "科技成长",
                    "投资机会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "后疫情时代，关注科技成长板块投资机会",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 3,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "领跌CRO淘金赛道：泰格医药转型“投资者”AB面 非经常性损益突出",
            "features": {
                "keywords": [
                    "CRO",
                    "泰格医药",
                    "转型",
                    "投资者",
                    "非经常性损益"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "领跌CRO淘金赛道：泰格医药转型“投资者”AB面 非经常性损益突出",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]